Study analysis · Journal of Pharmaceutical Innovation · 2025
A 12-week probiotic + vitamin D supplement lowered a nerve-damage marker in MS — but the abstract won't tell you by how much.
People with multiple sclerosis who took a probiotic and vitamin D supplement had lower blood levels of a nerve-damage marker than a control group, but we don't know the size of the drop.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at whether a supplement changed a marker in people with MS. Because we only have a short summary and don't know if people were randomly assigned or if it was blinded, we can't say the supplement caused the change—only that it was linked to a change. We need more details to be sure.
What’s the bottom line?
In people with multiple sclerosis, a 12-week supplement with probiotics and vitamin D reduced blood levels of NFL, a marker of nerve damage, compared with a control group. The study abstract says this is the first time probiotics have been shown to lower this marker in MS. The size of the drop and how many people were studied are not reported.
How strong is this study?
We don't have enough information about how the study was done—like how many people were in it, how they were assigned, or if anyone knew who got the supplement. That makes it hard to trust the results completely. The title says it was randomized and double-blind, but we can't confirm that from the abstract alone.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Randomization and blinding are not confirmed in the abstract; classification lists randomization as Unknown and blinding as Unknown. Without confirmed randomization and blinding, confounding and bias cannot be ruled out. Abstract-only data prevents assessment of temporality, dose-response, and consistency. Therefore, causal inference is not supported.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding disclosures are present in the provided text, so potential biases cannot be evaluated.
The provided text is only a brief results statement and lacks author affiliations, funding information, and any conflict of interest declaration. A full COI assessment is not possible from this excerpt.
Key takeaways
- 01
The supplement group had significantly lower NFL biomarker concentration than the control group after 12 weeks.
- 02
The abstract does not report how much lower (no relative or absolute reduction, no p-value, no sample size).
- 03
NFL is a blood marker of nerve damage.
- 04
A significant reduction sounds promising, but without the actual numbers (how much NFL fell, how many people, baseline risk) we cannot say how meaningful this is for patients.
- 05
The absolute reduction or extra cases avoided was not reported in this study.
Surprising findings
- First report that probiotic bacteria can reduce NFL biomarker in multiple sclerosis.If true, it would be a new mechanism for a supplement to affect a neurodegenerative disease marker, but the abstract provides no magnitude or statistical detail to support the claim.
Practical takeaways
Do not start a probiotic + vitamin D supplement specifically to lower NFL in MS based on this abstract alone.
Full paper not available; no effect size, sample size, or clinical outcomes reported; talk to a neurologist before changing treatment.
low confidenceIf you follow MS research, track whether the full trial reports absolute NFL changes and clinical outcomes like relapses or disability progression.
Abstract-only; methodology cannot be verified.
low confidenceWhy this study matters
NFL: The Nerve-Damage Blood Marker
The study measured serum neurofilament light chain (sNFL), a blood biomarker of neuroaxonal damage. After 12 weeks, the supplement group had significantly lower NFL concentration than controls, according to the abstract. No actual NFL numbers or effect size are reported.
NFL is a hot biomarker in MS research; lower NFL is generally viewed as less nerve damage, but without magnitude, clinical meaning is unclear.
First Time Probiotics Linked to Lower NFL
The abstract states: 'for the first time, the effect of probiotic bacteria on reducing this biomarker.' That novelty claim suggests prior trials had not shown this specific biomarker effect.
First-time claims grab attention, but they also need replication and full methods.
The 12-Week Trial vs Control
The comparison was a supplement containing probiotics and vitamin D versus a control group over twelve weeks. The abstract does not specify sample size, randomization, blinding, dosage, strains, or statistical details.
Without these details, we can't judge whether the result is reliable or clinically meaningful.
Gut-Brain Axis in MS
One claim says gut microbiome health can affect the course or risk of brain and nerve diseases. This study tests a probiotic + vitamin D supplement in MS, but the abstract doesn't establish a mechanism.
The gut-brain axis is a popular topic, but this abstract alone doesn't prove probiotics change MS course.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In people with multiple sclerosis, a 12-week supplement with probiotics and vitamin D reduced blood levels of NFL, a marker of nerve damage, compared with a control group. The study abstract says this is the first time probiotics have been shown to lower this marker in MS. The size of the drop and how many people were studied are not reported.
Research results
The supplement group had significantly lower NFL biomarker concentration than the control group after 12 weeks. The abstract does not report how much lower (no relative or absolute reduction, no p-value, no sample size).
What this means - more context
NFL is a blood marker of nerve damage. A significant reduction sounds promising, but without the actual numbers (how much NFL fell, how many people, baseline risk) we cannot say how meaningful this is for patients. The absolute reduction or extra cases avoided was not reported in this study.
To examine whether a novel supplement containing probiotics and vitamin D reduces serum neurofilament light chain (sNFL) and affects Th cell profiles in patients with multiple sclerosis.
In a 12-week trial, patients with multiple sclerosis taking a probiotic + vitamin D supplement had significantly lower NFL biomarker concentration than a control group. The abstract reports this as the first time probiotic bacteria have been shown to reduce this biomarker. The magnitude of reduction, sample size, and statistical details are not provided in the abstract.
Methods Used
Not specified in abstract beyond a 12-week supplement vs control comparison. The title describes a randomized, double-blind, placebo-controlled trial. Details on participants, randomization, blinding, supplement composition, and outcomes are not available in the abstract.
Main Finding
Consuming the probiotic + vitamin D supplement for 12 weeks significantly reduced NFL biomarker concentration compared with the control group. The abstract states this is the first report of probiotic bacteria reducing this biomarker in multiple sclerosis. Effect size, relative reduction, absolute reduction, and statistical significance values are not reported in the abstract.
Confidence Level
Limited - based on abstract only, full methodology not available. No effect size, sample size, p-values, or confidence intervals are reported in the abstract.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Effect size/magnitude and absolute reduction not reported in abstract
- •Sample size, randomization, blinding, and statistical details not specified in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
First report that probiotic bacteria can reduce NFL biomarker in multiple sclerosis.
If true, it would be a new mechanism for a supplement to affect a neurodegenerative disease marker, but the abstract provides no magnitude or statistical detail to support the claim.
Practical Takeaways
Do not start a probiotic + vitamin D supplement specifically to lower NFL in MS based on this abstract alone.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at whether a supplement changed a marker in people with MS. Because we only have a short summary and don't know if people were randomly assigned or if it was blinded, we can't say the supplement caused the change—only that it was linked to a change. We need more details to be sure.
Strengths
- Control group comparison mentioned in abstract
- 12-week intervention period
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status unknown
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In people with multiple sclerosis, a 12-week supplement with probiotics and vitamin D reduced blood levels of NFL, a marker of nerve damage, compared with a control group. The study abstract says this is the first time probiotics have been shown to lower this marker in MS. The size of the drop and how many people were studied are not reported.
Research results
The supplement group had significantly lower NFL biomarker concentration than the control group after 12 weeks. The abstract does not report how much lower (no relative or absolute reduction, no p-value, no sample size).
What this means - more context
NFL is a blood marker of nerve damage. A significant reduction sounds promising, but without the actual numbers (how much NFL fell, how many people, baseline risk) we cannot say how meaningful this is for patients. The absolute reduction or extra cases avoided was not reported in this study.
To examine whether a novel supplement containing probiotics and vitamin D reduces serum neurofilament light chain (sNFL) and affects Th cell profiles in patients with multiple sclerosis.
In a 12-week trial, patients with multiple sclerosis taking a probiotic + vitamin D supplement had significantly lower NFL biomarker concentration than a control group. The abstract reports this as the first time probiotic bacteria have been shown to reduce this biomarker. The magnitude of reduction, sample size, and statistical details are not provided in the abstract.
Methods Used
Not specified in abstract beyond a 12-week supplement vs control comparison. The title describes a randomized, double-blind, placebo-controlled trial. Details on participants, randomization, blinding, supplement composition, and outcomes are not available in the abstract.
Main Finding
Consuming the probiotic + vitamin D supplement for 12 weeks significantly reduced NFL biomarker concentration compared with the control group. The abstract states this is the first report of probiotic bacteria reducing this biomarker in multiple sclerosis. Effect size, relative reduction, absolute reduction, and statistical significance values are not reported in the abstract.
Confidence Level
Limited - based on abstract only, full methodology not available. No effect size, sample size, p-values, or confidence intervals are reported in the abstract.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Effect size/magnitude and absolute reduction not reported in abstract
- •Sample size, randomization, blinding, and statistical details not specified in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
First report that probiotic bacteria can reduce NFL biomarker in multiple sclerosis.
If true, it would be a new mechanism for a supplement to affect a neurodegenerative disease marker, but the abstract provides no magnitude or statistical detail to support the claim.
Practical Takeaways
Do not start a probiotic + vitamin D supplement specifically to lower NFL in MS based on this abstract alone.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at whether a supplement changed a marker in people with MS. Because we only have a short summary and don't know if people were randomly assigned or if it was blinded, we can't say the supplement caused the change—only that it was linked to a change. We need more details to be sure.
Strengths
- Control group comparison mentioned in abstract
- 12-week intervention period
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status unknown
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
We don't have enough information about how the study was done—like how many people were in it, how they were assigned, or if anyone knew who got the supplement. That makes it hard to trust the results completely. The title says it was randomized and double-blind, but we can't confirm that from the abstract alone.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
31 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Randomization and blinding are not confirmed in the abstract; classification lists randomization as Unknown and blinding as Unknown. Without confirmed randomization and blinding, confounding and bias cannot be ruled out. Abstract-only data prevents assessment of temporality, dose-response, and consistency. Therefore, causal inference is not supported.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding disclosures are present in the provided text, so potential biases cannot be evaluated.
The provided text is only a brief results statement and lacks author affiliations, funding information, and any conflict of interest declaration. A full COI assessment is not possible from this excerpt.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
8 researchersIf this is your work, this is how we attribute it on Fit Body Science. Alireza Zali is listed as the lead author.
- Amir Mohammad MortazavianCorrespondingNational Nutrition and Food Technology Research Institute